Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, et al.
Nature Medicine|January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
Blood Advances|December 14, 2022
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphomaNarendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, et al.
Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.
The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.
The Journal of Infectious Diseases|July 25, 2024
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic LeukemiaElise A Chong, Kingsley Gideon Kumashie, Emeline R Chong, et al.
Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Blood Advances|October 24, 2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphomaJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Blood Advances|May 13, 2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomasRahul S Bhansali, Fredrik Ellin, Thomas Relander, et al.
Pageof 4